Gamida Cell: Omidubicel Follow Up Data Shows 63% Overall Survival At Three Years

Gamida Cell Ltd. (GMDA) reported long term follow-up data and health-related quality of life scores of patients treated with omidubicel in patients with blood cancers. The data showed an overall survival and disease-free survival of 63% and 56% at three years, respectively, as well as durable long-term hematopoiesis and immune competence.

Overall well-being health-related quality of life scores for patients treated with omidubicel showed clinical benefit compared to standard of care, the company said.

Ronit Simantov, Chief Medical Officer of Gamida Cell, said: "As we approach the PDUFA date of January 30, 2023, and upon potential FDA approval, we are prepared to execute our plan that ensures access to those patients who can benefit from omidubicel as quickly as possible."

For More Such Health News, visit rttnews.com.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Foxconn, Apple Inc.'s key iPhone assembler, expects that its major plant in China, which is being hit hard by worker unrest following Covid-19 spread and related restrictions, would restart full production around late December to early January, Reuters reported citing a Foxconn source. Nestle Purina PetCare Co. has recalled a limited amount of certain prescription wet dog food citing labeling error, the U.S. Food and Drug Administration said. The recall involves Purina Pro Plan Veterinary Diets EN Gastroenteric Low Fat or PPVD EN Low Fat wet dog food that comes in 13.4 oz cans. Exportadora Copramar is recalling 1260 cases of James Farm frozen raspberries citing potential to be contaminated with Hepatitis A, the U.S. Food and Drug Administration said. The recall involves James Farm branded frozen raspberries identified by UPC Code: 76069501010 and Lot Code - 22-165.
Follow RTT